Last reviewed · How we verify
Olmesartan/Amlodipin
Olmesartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.
Olmesartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload. Used for Hypertension.
At a glance
| Generic name | Olmesartan/Amlodipin |
|---|---|
| Also known as | Sevikar(r) |
| Sponsor | Institut für Pharmakologie und Präventive Medizin |
| Drug class | Angiotensin II receptor blocker / Calcium channel blocker combination |
| Target | AT1 receptor (angiotensin II type 1 receptor) / L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (CCB). Olmesartan prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine inhibits L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reduced contractility. Together, they provide complementary antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Peripheral edema
- Dizziness
- Headache
- Fatigue
- Hyperkalemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olmesartan/Amlodipin CI brief — competitive landscape report
- Olmesartan/Amlodipin updates RSS · CI watch RSS
- Institut für Pharmakologie und Präventive Medizin portfolio CI